Concord Wealth Partners Biomarin Pharmaceutical Inc Transaction History

Concord Wealth Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$71.48 - $86.85 $19,942 - $24,231	-279 Closed	0 $0
Q1 2022 Apr 20, 2022	BUY	$74.28 - $92.69 $5,051 - $6,302	68 Added 32.23%	279 $22,000
Q4 2021 Jan 21, 2022	BUY	$71.72 - $91.47 $11,475 - $14,635	160 Added 313.73%	211 $19,000
Q3 2021 Nov 09, 2021	BUY	$74.77 - $85.47 $3,140 - $3,589	42 Added 466.67%	51 $4,000
Q1 2021 May 13, 2021	BUY	$74.73 - $90.69 $672 - $816	9 New	9 $1,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.